Anti-Human/Mouse IL-10 (Clone JES3-9D7) – Biotin

Recombinant human IL-10

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

ELISA,
FA,
FC,
IHC,
WB

JES3-9D7 activity is directed against human and mouse interleukin-10 (IL-10).

Interleukin-10 (IL-10) is a homodimeric, anti-inflammatory cytokine of 17-21 kD¹. It was initially discovered because of its ability to inhibit the synthesis of various pro-inflammatory cytokines produced by T helper 1 (Th1) cells. It plays a vital role in regulating the immune response and inflammation². IL-10 has diverse effects and can either suppress or promote immune responses based on the circumstances. Its anti-inflammatory properties include inhibiting the activity of Th1 cells, natural killer (NK) cells, and macrophages. These cells play a role in clearing pathogens but can also lead to tissue damage^3-7. IL-10 supports the activation of B-cells and CD8+ T-cells and is involved in peripheral T-cell tolerance to allergens, autoantigens, transplantation antigens, and tumor antigens⁸.

The dysregulation of IL-10 has been linked to an increased risk of autoimmune diseases and enhanced immunopathology in response to infection. In mice, the absence of IL-10 has been shown to cause inflammation and pain by COX activation, leading to dysfunctions in the vascular endothelial and cardiac systems. Studies in which IL-10 was knocked out suggest that this cytokine plays a crucial role in counteracting the hyperactive immune response in the intestinal tract. It has been reported that the treatment of Crohn’s disease patients with recombinant IL-10-producing bacteria has been beneficial. IL- 10 is associated with certain diseases such as Graft-Versus-Host Disease and Human Immunodeficiency Virus Type 1⁹.

JES3-9D7 is a monoclonal antibody that specifically targets and neutralizes human and mouse IL-10. It has been extensively studied for its ability to inhibit the biological activity of IL-10 and its potential therapeutic applications^10,11.

IL-10 is produced by various immune cells, including T cells, B cells, macrophages, and dendritic cells.

IL-10R (CDw210)

1. Isac L, Jiquan S. Interleukin 10 promotor gene polymorphism in the pathogenesis of psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2019;28(3):119-123.
2. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med.2007;204(2):239-243.
3. Ng THS, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.
4. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995;27(5):537-541.
5. Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol. 1999;29(9):2658-2665.
6. Kubo M, Motomura Y. Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. Front Immunol. 2012;3:275.
7. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(4):465-475.
8. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol. 2003;11(3-4):267-276.
9. Geginat J, Larghi P, Paroni M, et al. The light and the dark sides of Interleukin-10 in immune- mediated diseases and cancer. Cytokine Growth Factor Rev. 2016;30:87-93.
10. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A. 1993;90(23):11267-11271.
11. Sabat R, Seifert M, Volk HD, Glaser RW. Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Mol Immunol. 1996;33(14):1103-1111.
12. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992;127:5-24.
13. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martínez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine. 1992;4(5):385-390.
14. Yssel H, De Waal Malefyt R, Roncarolo MG, et al. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol. 1992;149(7):2378-2384.
15. Burdin N, Van Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol. 1995;154(6):2533-2544.
16. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102(1):98-106.
17. Smith DR, Kunkel SL, Burdick MD, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol. 1994;145(1):18-25.